Counterfeit Medicine
A counterfeit medicine is one deliberately and fraudulently misrepresented as to identity or source, a definition about deception of origin rather than about whether the contents are chemically correct.
Counterfeiting is defined by fraud about provenance. A counterfeit product misrepresents what it is, who made it or where it came from, and it may contain the right drug, the wrong drug, the right drug at the wrong strength, or no active ingredient at all. The World Health Organization moved away from the word because it entangled trademark disputes with public health, and now uses substandard and falsified as the operative categories.
Incretin products are the clearest recent case. In late 2023 regulators and the manufacturer warned that counterfeit units of a semaglutide product, including counterfeit pen components and needles, had been recovered from legitimate United States distribution, and in 2024 the WHO issued a global alert on falsified semaglutide after seizures in several regions. Analyses of seized pens in more than one country found insulin rather than a glucagon-like peptide-1 agonist, and hospital admissions for hypoglycaemia followed.
Counterfeiting concentrates where price, demand and scarcity coincide, so risk is not spread evenly across a pharmacopoeia; a cheap, plentiful drug is rarely worth faking. The consumer-visible defences are packaging-level ones such as serialisation, tamper evidence and print quality, and those are exactly what a competent operation reproduces. The stronger control is custody, an unbroken chain from manufacturer through licensed distribution.
Two mirror-image errors recur. The first assumes a counterfeit is inert, making wasted money the worst case; the insulin findings show the worst case is an active drug at a dangerous dose in someone not expecting it. The second treats a clean assay as exoneration, confusing composition with origin: a falsified product whose contents test correct still has an unknown manufacturing, sterility and temperature history, with no recall or pharmacovigilance route attached to it.